Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Bind Therapeutics
Bind Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
PeptiDream to collaborate with BIND Therapeutics
To investigate the use of the firm's macrocyclic peptides as the targeting ligand on BIND’s Accurin nanoparticles
Research & Development
BIND Therapeutics and Roche collaborate on discovery of novel nanomedicines
Collaboration will focus on combining BIND\'s technology with Roche\'s proprietary therapeutic payloads and targeting ligands
You need to be a subscriber to read this article.
Click here
to find out more.
Drug Delivery
Helping the delivery of biotech-based therapies
Modern biotech-derived medicines require new methods to aid targeted delivery. Dr Sarah Houlton, looks at some of the novel nano-based technologies that are getting results
Research & Development
AstraZeneca and Bind Therapeutics sign cancer nanomedicine agreement
Bind could be eligible for US$200m in payments through Accurin deal
Research & Development
Pfizer signs deal with Bind Therapeutics
To develop and commercialist Accurins using Bind nanoengineering technology
Subscribe now